Clinical Trial Update: A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers [Phase 1]

View source ↗

Summary

Completed Phase 1 trial evaluating the safety, reactogenicity, and immunogenicity of MVA-BN Yellow Fever Vaccine with and without Montanide ISA-720 Adjuvant in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Yellow Fever

Drugs mentioned

• MVA-BN Yellow Fever Vaccine (Modified vaccinia Ankara-BN Yellow Fever vaccine)
• Montanide ISA-720 Adjuvant (Montanide ISA-720 adjuvant)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Yellow Fever, Yellow Fever Immunisation | Phase 1 | Status: COMPLETED